These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24614383)

  • 1. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.
    Savic RM; Lu Y; Bliven-Sizemore E; Weiner M; Nuermberger E; Burman W; Dorman SE; Dooley KE
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3035-42. PubMed ID: 24614383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
    Hibma JE; Radtke KK; Dorman SE; Jindani A; Dooley KE; Weiner M; McIlleron HM; Savic RM
    Am J Respir Crit Care Med; 2020 Sep; 202(6):866-877. PubMed ID: 32412342
    [No Abstract]   [Full Text] [Related]  

  • 3. A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.
    Francis J; Zvada SP; Denti P; Hatherill M; Charalambous S; Mungofa S; Dawson R; Dorman S; Gupte N; Wiesner L; Jindani A; Harrison TS; Olagunju A; Egan D; Owen A; McIlleron HM
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.
    Zvada SP; Van Der Walt JS; Smith PJ; Fourie PB; Roscigno G; Mitchison D; Simonsson US; McIlleron HM
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3390-4. PubMed ID: 20516273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.
    Langdon G; Wilkins J; McFadyen L; McIlleron H; Smith P; Simonsson US
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4429-36. PubMed ID: 16251279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.
    Dooley KE; Savic RM; Park JG; Cramer Y; Hafner R; Hogg E; Janik J; Marzinke MA; Patterson K; Benson CA; Hovind L; Dorman SE; Haas DW;
    Antimicrob Agents Chemother; 2015; 59(6):3399-405. PubMed ID: 25824215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
    Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
    Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
    Weiner M; Bock N; Peloquin CA; Burman WJ; Khan A; Vernon A; Zhao Z; Weis S; Sterling TR; Hayden K; Goldberg S;
    Am J Respir Crit Care Med; 2004 Jun; 169(11):1191-7. PubMed ID: 14962821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.
    Wilkins JJ; Savic RM; Karlsson MO; Langdon G; McIlleron H; Pillai G; Smith PJ; Simonsson US
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2138-48. PubMed ID: 18391026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study.
    Keung AC; Owens RC; Eller MG; Weir SJ; Nicolau DP; Nightingale CH
    Antimicrob Agents Chemother; 1999 May; 43(5):1230-3. PubMed ID: 10223941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
    Pham MM; Podany AT; Mwelase N; Supparatpinyo K; Mohapi L; Gupta A; Samaneka W; Omoz-Oarhe A; Langat D; Benson CA; Chaisson RE; Swindells S; Fletcher CV
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0238521. PubMed ID: 35943252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
    Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifapentine: its role in the treatment of tuberculosis.
    Temple ME; Nahata MC
    Ann Pharmacother; 1999 Nov; 33(11):1203-10. PubMed ID: 10573321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifapentine pharmacokinetics in adolescents.
    Marshall JD; Abdel-Rahman S; Johnson K; Kauffman RE; Kearns GL
    Pediatr Infect Dis J; 1999 Oct; 18(10):882-8. PubMed ID: 10530584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.
    Brooks KM; George JM; Pau AK; Rupert A; Mehaffy C; De P; Dobos KM; Kellogg A; McLaughlin M; McManus M; Alfaro RM; Hadigan C; Kovacs JA; Kumar P
    Clin Infect Dis; 2018 Jul; 67(2):193-201. PubMed ID: 29415190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose pharmacokinetics of rifapentine in women.
    Keung AC; Eller MG; Weir SJ
    J Pharmacokinet Biopharm; 1998 Feb; 26(1):75-85. PubMed ID: 9773393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects.
    Conte JE; Golden JA; McQuitty M; Kipps J; Lin ET; Zurlinden E
    Antimicrob Agents Chemother; 2000 Apr; 44(4):985-90. PubMed ID: 10722501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I.
    Keung A; Reith K; Eller MG; McKenzie KA; Cheng L; Weir SJ
    Int J Tuberc Lung Dis; 1999 May; 3(5):426-36. PubMed ID: 10331733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.
    Zurlinden TJ; Eppers GJ; Reisfeld B
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4860-8. PubMed ID: 27270284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single and multiple dose pharmacokinetics of rifapentine in man: part II.
    Keung A; Eller MG; McKenzie KA; Weir SJ
    Int J Tuberc Lung Dis; 1999 May; 3(5):437-44. PubMed ID: 10331734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.